Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13719MR)

This product GTTS-WQ13719MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13719MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3930MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ9885MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ10076MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ13197MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ3914MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ14398MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ8598MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ9345MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCAGN-01876
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW